ArticleCell communication and signaling : CCS2026
Polyubiquitination and accumulation of PEG10 regulated by SIAH1/2 affiliates the progression of hepatocellular carcinoma.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSIAH1 and SIAH2 are key regulators of hepatocellular carcinoma (HCC) initiation and progression, but their precise molecular mechanisms remain unclear. Although both interact with the oncoprotein PEG10, it is unknown whether PEG10 mediates their regulatory effects on HCC or what the underlying mechanisms are.
methodsThe effects of SIAH1/2 on HCC cell proliferation and metastasis were assessed in vitro and in vivo by EdU, colony formation, transwell assays, and tumor xenograft models. Co-immunoprecipitation, ubiquitination assays, and site-directed mutagenesis were applied to investigate the interaction with PEG10 and the specific ubiquitination mechanisms. Clinical samples were used for analyzing the correlation between SIAH1/2 and PEG10 protein expression in HCC patients.
resultsWe demonstrated that SIAH1 and SIAH2 played opposing roles in HCC: SIAH1 suppressed cell proliferation and metastasis, whereas SIAH2 promoted these processes. Mechanistically, both proteins bound to the PAIR domain of PEG10 and promoted its polyubiquitination via K48/63-linked chains. However, they differed in lysine specificity: SIAH1 mainly mediated K48-linked ubiquitination at Lys 36 and K63-linked ubiquitination at Lys 170 of PEG10, whereas SIAH2 primarily mediated K48-linked ubiquitination at Lys 36, and K63-linked ubiquitination at Lys 19 and Lys 155. In vivo analyses confirmed that SIAH1 expression negatively correlated with PEG10 protein levels, while SIAH2 showed a positive correlation.
conclusionsOur study reveals that SIAH1 and SIAH2 differentially regulate HCC progression by modulating PEG10 stability through distinct ubiquitination site targeting. These findings elucidate a key molecular mechanism in HCC and highlight the SIAH-PEG10 axis as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.